Articles related to MYELOMA

AL amyloidosis can present with distinctive periorbital signs, including petechiae and waxy eyelid papules, which may worsen with trauma.

AL amyloidosis, a rare disease with an estimated global incidence of 10 cases per million population, can present with various symptoms depending on organ involvement, making early diagnosis challenging but crucial for effective treatment.

Infections account for over 50% of nonrelapse deaths in CAR T-cell therapy patients, outweighing therapy-specific toxicities like ICANS and CRS.

Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.

Secondary malignancies like indolent CD4+ CAR T-cell lymphoma can emerge after CAR T-cell therapy. This case highlights the importance of recognizing and thoroughly investigating these rare complications.

A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.